References
- World Health Organization. Pneumococcal conjugate vaccine for childhood immunization – WHO position paper. Wkly Epidemiol Rec. 2007;82(12):93–104.17380597
- Ardanuy C, Pallares R, Fenoll A, Lin J. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect. 2010;16:402–410. doi:10.1111/j.1469-0691.2010.03182.x20132251
- Pallares R, Gudiol F, Liñares J, et al. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N Engl J Med. 1987;317:18–22. doi:10.1056/NEJM1987070231701043587309
- Riedel S, Beekmann SE, Heilmann KP, et al. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis. 2007;(26):485–490. doi:10.1007/s10096-007-0321-517551759
- The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.1; 2018 Available from: http://Www.Eucast.Org. Accessed May 21, 2019.
- European Centre for Disease Prevention and Control. Surveillance atlas of infectious diseases; 2017 Available from: https://ecdc.europa.eu/en/surveillance-atlas-infectious-diseases. Accessed 1123, 2018.
- Zhanel GG, Baxter MR, Adam HJ, Sutcliffe J, Karlowsky JA. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories : CANWARD surveillance study 2014 – 2015. Diagnostic Microbiol Infect Dis. 2018;91(1):55–62. doi:10.1016/j.diagmicrobio.2017.12.013
- Durata Therapeutics Holding C.V. Full prescribing information DALVANCE® (dalbavancin) [package insert]. 2018;1–20.
- Astellas Pharma US. Full prescribing information VIBATIV (telavancin) [package insert]. 2009.
- Merck Sharp & Dohme Corp. Full Prescribing Information SIVEXTRO® (Tedizolid Phosphate) [package insert]. 2017;1–17
- Melinta Therapeutics. Full prescribing information BAXDELATM (delafloxacin) [package insert]. 2017.
- CLSI M100-ED28:2018 Performance Standards for Antimicrobial Susceptibility Testing. 28th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
- Jorgensen SCJ, Mercuro NJ, Davis SL. Delafloxacin : place in therapy and review of microbiologic, clinical and pharmacologic properties. Infect Dis Ther. 2018;7(2):197–217. doi:10.1007/s40121-018-0198-x29605887
- Tetraphase Pharmaceuticals Inc. Full prescribing information XERAVA (eravacycline) [package insert]. 2018.
- Connors KP, Housman ST, Pope JS, et al. Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Antimicorbial Agents Chemother. 2014;58(4):2113–2118. doi:10.1128/AAC.02036-13
- Grebe T, Hakenbeck R. Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of  -lactam antibiotics. Antimicorbial Agents Chemother. 1996;40(4):829–834. doi:10.1128/AAC.40.4.829
- Mousavi SF, Pana M, Feizabadi M, et al. Diversity of mosaic pbp2x families in penicillin-resistant Streptococcus pneumoniae from Iran and Romania. Antimicorbial Agents Chemother. 2017;61(12):1–12.